[Monitoring of bone metastases]

Current knowledge about an incidence of bone metastases, use of bisphosphonates and assessment of response to the treatment are surveyed. The bone metastases are quite frequent in patients with breast and prostate cancers. High doses of intravenous pamidronate are particularly useful in the treatment of these patients. Prior to therapy with bisphosphonate special score elaborated by RE Coleman should be calculated. The new biochemical bone resorption markers especially Ntx i Crosslaps seems to be the most efficient for evaluation metastases response.